EUCTR2007-003089-16-DE进行中（未招募）不适用
Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Women, 18 years and older, written (signed and dated) informed consent
- •Histological confirmed epithelial ovarian cancer, primary cancer of the peritoneum or fallopian tube
- •Up to three prior chemotherapies, at least one platinum based chemotherapy
- •Platinum refractory or resistant ovarian cancer (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or treatment free interval < 6 months after stop of platinum based chemotherapy)
- •Measurable or non-measurable disease
- •Elevated CA°125 level (> 2 x ULN in case of normal CA°125 after prior chemotherapy; or = 2 x nadir CA°125 value after prior chemotherapy, when CA°125 levels remained elevated above normal) in case of non-measurable disease
- •ECOG performance status 0-2
- •Negative pregnancy test within 5 days before randomization and adequate contraception in women with childbearing potential
- •Adequate organ function as defined by the following criteria:
- •Serum aspartate aminotransferase (AST; serum glutamate-oxalate transferase [SGOT]) and serum alanine aminotransferase (ALT; serum glutamate-pyruvate transferase [SGPT]) ?2.5 x upper limit of normal (ULN). If liver function abnormalities are due to underlying malignancy, then AST and ALT may be ?5 x ULN
- •Total serum bilirubin ?1.5 x ULN
- •Prothrombin time (PT) and partial thromboplastin time (PTT) ?1.5 x ULN
- •Serum albumin ?3.0 g/dL
- •Absolute neutrophil count (ANC) ?1500/?L
- •Platelets ?100,000/?L
- •Hemoglobin ?9.0 g/dL
- •Serum creatinine ?1.5 x ULN
- •TSH within normal range
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- •Resolution of all toxic effects of any prior chemotherapy, surgical procedures, radiotherapy, or other cancer related therapies to NCI CTCAE (Version 3.0) grade ?1 and to the baseline laboratory values as defined in inclusion criterion (see before)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Borderline tumor of the ovaries
- •Acute or chronic infection
- •Any required concurrent cancer chemotherapy or antineoplastic endocrine therapy or radiotherapy
- •Exposure to investigational trial medication, cancer chemo- or radiotherapy within the last 28 days prior to start of study treatment
- •Known or suspected hypersensitivity to investigational compound
- •Second malignancy interfering with prognosis of the patient
- •Inadequate renal function (Creatinine >1.5 x ULN)
- •Inadequate hepatic function (ASAT, ALAT, GGT >2.5 x ULN, in case of liver metastases >5.0 x ULN; Bilirubine >1.5 x ULN)
- •Platelets < 100.000 /µl; ANC < 1.500 /µl
- •Cachectic patients with a body weight <45 kg
- •Patients requiring parenteral nutrition
- •Patients with ileus within the last 28 days
- •Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event
- •Current treatment with therapeutic doses of anticoagulant (low dose Cumarin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed)
- •Current treatment with CYP3A4 inhibitors or –inducers
- •Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
- •Ongoing cardiac dysrhythmias of NCI CTCAE grade ?2, atrial fibrillation of any grade, or prolongation of the QTc interval to >470 msec for females
- •Left ventricular ejection fraction (LVEF) ?50% as measured by echocardiogram (ECHO)
- •NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment
- •Evidence of neurological signs/symptoms suggestive of brain metastases, spinal cord compression, or new evidence of brain or leptomeningeal disease
- •Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS)-related illness
- •Patients with any other severe concurrent disease, which is an undue risk for the patient by participating in the present study
- •Any further condition which according to the investigator results in an undue risk of the patient by participating in the present study
- •Major surgery, radiation therapy, or systemic therapy within 3 weeks of first study treatment. At least 7 days should elapse from the time of minor surgical procedure including placement of an access device or fine needle aspiration before randomization into this study can occur.
- •Wounds that have not completely healed, active ulcer(s), or bone fracture(s).
- •Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
- •Prior radiation therapy to >25% of the bone marrow.
研究者
相似试验
已完成
2 期
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase InhibitorPlatinum Refractory Epithelial Ovarian CancerPrimary Cancer of the PeritoneumCancer of the Fallopian TubeNCT00543049AGO Study Group73
已完成
2 期
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian CarcinomaOvarian CarcinomaRelapseNCT01481701Jules Bordet Institute90
进行中（未招募）
不适用
Cabazitaxel in ovarian cancer patients who do not respond to platinum-based chemotherapy. A phase II trialEUCTR2012-001224-35-DKVejle Hospital
已完成
3 期
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian CancerOvarian CancerNCT04908787Jiangsu Simcere Pharmaceutical Co., Ltd.421
已完成
2 期
Continuous administration trial of Bevacizumab for platinum-resistant recurrent ovarian cancer patientsplatinum-resistant recurrent ovarian cancerhistologically confirmed epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancerJPRN-jRCTs031180244Shoji Tadahiro103